Loading
A phase 2 trial of BNT324 and PM8002 in advanced solid tumours, run by DualityBio Inc., now recruiting.
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-05-22: recruiting. Enrollment is planned at 450 participants. Primary completion is estimated at 2030-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: DB-1311/BNT324, BNT327, DB-1305/BNT325. Registered primary measures: Part 1: Number of participants with Dose Limiting Toxicities (DLTs).; Part 1: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs); Part 2: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs) [By arm and dose level].
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DB-1305 / BNT325, Duality Biotherapeutics, PM8002, BioNTech and the tag pipeline.
Shares BNT324, Duality Biotherapeutics, PM8002, BioNTech and the tag pipeline.
Shares BNT324, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/